Akums Drugs and Pharmaceuticals Limited (AKUMS) Stock Forecast & Price Target

Compare

4 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AKUMS Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Akums

Drugs and Pharmaceuticals Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AKUMS Stock 12 Month Forecast

Average Price Target

₹600.00

▲(42.82% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Akums Drugs and Pharmaceuticals Limited in the last 3 months. The average price target is ₹600.00 with a high forecast of ₹600.00 and a low forecast of ₹600.00. The average price target represents a 42.82% change from the last price of ₹420.10.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"423":"₹423","938":"₹938","551.75":"₹551.8","680.5":"₹680.5","809.25":"₹809.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹600.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹600.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹600.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[423,551.75,680.5,809.25,938],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Jan<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,424.05,437.5846153846154,451.1192307692308,464.6538461538462,478.1884615384615,491.7230769230769,505.2576923076923,518.7923076923078,532.3269230769231,545.8615384615384,559.3961538461539,572.9307692307692,586.4653846153847,{"y":600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,424.05,437.5846153846154,451.1192307692308,464.6538461538462,478.1884615384615,491.7230769230769,505.2576923076923,518.7923076923078,532.3269230769231,545.8615384615384,559.3961538461539,572.9307692307692,586.4653846153847,{"y":600,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,424.05,437.5846153846154,451.1192307692308,464.6538461538462,478.1884615384615,491.7230769230769,505.2576923076923,518.7923076923078,532.3269230769231,545.8615384615384,559.3961538461539,572.9307692307692,586.4653846153847,{"y":600,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":937.35,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":937.35,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":937.35,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":937.35,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":832.65,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":867.6,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":841.1,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":617.3,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":633.5,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":633.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":514.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":424.05,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹600.00

Average Price Target₹600.00

Lowest Price Target₹600.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Abdulkader Puranwala

ICICI Securities

₹600

Buy

42.82%

Upside

Reiterated

12/22/25

Vivek Agrawal CFA

Citi

₹700

Buy

66.63%

Upside

Initiated

03/12/25

Citi Starts Akums Drugs #x26; Pharmaceuticals (AKUMS:IN) at BuyCiti analyst Vivek Agrawal initiates coverage on Akums Drugs Pharmaceuticals (AKUMS:IN) with a Buy rating and a price target of INR700.00.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Abdulkader Puranwala

ICICI Securities

₹600

Buy

42.82%

Upside

Reiterated

12/22/25

Vivek Agrawal CFA

Citi

₹700

Buy

66.63%

Upside

Initiated

03/12/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Akums Drugs and Pharmaceuticals Limited

3 Months

xxx

Success Rate

0/2 ratings generated profit

Average Return

-12.75%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -12.75% per trade.

1 Year

Abdulkader PuranwalaICICI Securities

Success Rate

0/2 ratings generated profit

Average Return

-18.30%

reiterated a buy rating last month

Copying Abdulkader Puranwala's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -18.30% per trade.

2 Years

xxx

Success Rate

0/2 ratings generated profit

Average Return

-18.30%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -18.30% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AKUMS Analyst Recommendation Trends

Rating

Jan 25

Mar 25

Aug 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AKUMS has received 5 Buy Ratings, 5 Hold Ratings, and 0 Sell Ratings. AKUMS average Analyst price target in the past 3 months is 600.00.

Each month's total comprises the sum of three months' worth of ratings.

AKUMS Financial Forecast

AKUMS Earnings Forecast

The previous quarter’s earnings for AKUMS were ₹2.60.

AKUMS Sales Forecast

Next quarter’s sales forecast for AKUMS is ₹10.64B with a range of ₹10.39B to ₹10.90B. The previous quarter’s sales results were ₹10.18B. AKUMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year AKUMS has Performed in-line its overall industry.

AKUMS Stock Forecast FAQ

What is IN:AKUMS’s average 12-month price target, according to analysts?

Based on analyst ratings, Akums Drugs and Pharmaceuticals Limited’s 12-month average price target is 600.00.

What is IN:AKUMS’s upside potential, based on the analysts’ average price target?

Akums Drugs and Pharmaceuticals Limited has 42.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Akums Drugs and Pharmaceuticals Limited a Buy, Sell or Hold?

Akums Drugs and Pharmaceuticals Limited has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Akums Drugs and Pharmaceuticals Limited’s share price target?

The average share price target for Akums Drugs and Pharmaceuticals Limited is 600.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹600.00 ,and the lowest forecast is ₹600.00. The average share price target represents 42.82% Increase from the current price of ₹420.1.

What do analysts say about Akums Drugs and Pharmaceuticals Limited?

Akums Drugs and Pharmaceuticals Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Akums Drugs and Pharmaceuticals Limited?

To buy shares of IN:AKUMS, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Akums Drugs and Pharmaceuticals Limited (AKUMS) Stock Forecast & Price Target

AKUMS Analyst Ratings

AKUMS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Akums Drugs and Pharmaceuticals Limited

AKUMS Analyst Recommendation Trends

AKUMS Financial Forecast

AKUMS Earnings Forecast

AKUMS Sales Forecast

AKUMS Stock Forecast FAQ

Detailed List of Analyst Forecasts